Eisai Downplayed Drug's 'Homicidal' Side Effects, FDA Says
An Eisai Inc. sales representative downplayed the potential for epilepsy drug Fycompa to make patients think about killing people and promoted the product for off-label uses, the U.S. Food and Drug...To view the full article, register now.
Already a subscriber? Click here to view full article